Can-Fite BioPharma is pursuing global licensing and strategic partnerships at BIO-Europe 2026, leveraging positive Phase IIa results in pancreatic cancer and ongoing pivotal Phase III trials in liver cancer and psoriasis. The company also expands its patent portfolio, including rare diseases like Lowe syndrome, to enhance commercial opportunities. With existing regional deals generating $20 million, Can-Fite aims to accelerate development and broaden global commercialization through new collaborations. This move highlights Can-Fite's growing clinical pipeline and strategic focus on oncology and inflammatory diseases.
Can-Fite BioPharma's recent clinical and intellectual property milestones provide context for readers interested in health sector trends. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 18:31 WIB: out of 150 priced US health-sector stocks, 47 rose and 94 fell. Notably, TransMedics Group Inc (TMDX) surged 11.83% to USD 77.14 with 100% buy orders and a typical hold time of 26 days, contrasting with DENTSPLY SIRONA Inc (XRAY), which dropped 10.80% to USD 9.00 and Globus Medical Inc. Class A (GMED), down 9.13% at USD 74.08 but also with 100% buy orders and a shorter hold time of 13 days.
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
The Indonesia data center market is projected to grow from USD 2.08 billion in 2027 to USD 4.05 billion by 2032, at a CAGR of 14.28%. Growth is fueled by expanding hyperscaler cloud infrastructure, rising digital workloads, increasing demand for colo...
The S&P 500 Dividend Aristocrats, a group of 68 companies that have increased their dividends for at least 25 consecutive years, have recently outperformed the broader market. These stocks are favored by investors seeking steady and reliable dividend...
Emergent BioSolutions lowered its FY26 revenue and EBITDA guidance due to delays in government purchases and ongoing pricing pressure in the U.S. naloxone market. The company reported a sharp decline in gross margin and profitability, with adjusted E...
